Last reviewed · How we verify
Cannabis Extract Oil SR Capsule
Cannabis extract oil modulates endocannabinoid system signaling through cannabinoid receptors (CB1 and CB2) to produce therapeutic effects.
Cannabis extract oil modulates endocannabinoid system signaling through cannabinoid receptors (CB1 and CB2) to produce therapeutic effects. Used for Chronic pain, Epilepsy, Multiple sclerosis-related spasticity.
At a glance
| Generic name | Cannabis Extract Oil SR Capsule |
|---|---|
| Sponsor | University of Sao Paulo General Hospital |
| Drug class | Cannabinoid receptor modulator |
| Target | CB1 receptor, CB2 receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology, Pain Management, Psychiatry |
| Phase | FDA-approved |
Mechanism of action
The extract contains phytocannabinoids, primarily CBD and THC, which interact with CB1 receptors in the central nervous system and CB2 receptors in peripheral immune tissues. This modulation affects pain perception, inflammation, anxiety, and other physiological processes. The sustained-release formulation provides prolonged therapeutic exposure.
Approved indications
- Chronic pain
- Epilepsy
- Multiple sclerosis-related spasticity
- Anxiety disorders
Common side effects
- Dizziness
- Drowsiness
- Dry mouth
- Fatigue
- Cognitive effects
Key clinical trials
- Randomized, Double-blind, Placebo-controlled Cannabis Extract x Placebo for Cocaine Addicts (PHASE4)
- Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: